Overview

Neupro is a dopamine agonist indicated for the treatment of Parkinson’s disease and moderate-to-severe primary Restless Legs Syndrome.

Coverage Guidelines

Authorization may be granted when the following criteria has been met:

- Member has a diagnosis of PD or RLS AND
- Member has a documented diagnosis of a swallowing disorder or difficulty swallowing tablets OR
- Member has had a documented side effect, allergy, or treatment failure to a trial of an oral dopamine agonist (e.g., pramipexole, or ropinirole)

Limitations

1. Approvals will be granted for 36 months.
2. A quantity limit of #30 patches per month applies.

Appendix

<table>
<thead>
<tr>
<th>Standard Dosing</th>
<th>Parkinson’s Disease</th>
<th>Restless Legs Syndrome</th>
</tr>
</thead>
</table>

399 Revolution Drive, Suite 810, Somerville, MA 02145 | allwayshealthpartners.org

AllWays Health Partners includes AllWays Health Partners, Inc. and AllWays Health Partners Insurance Company
<table>
<thead>
<tr>
<th><strong>Apply once a day to non-oily, irritated, or damaged skin, pressing firmly in place for 30 seconds.</strong></th>
<th><strong>Initial:</strong> 2 mg/24 hours for early-stage disease or 4 mg/24 hours for advanced-stage disease. The dose may be increased as needed by 2 mg/24 hours at weekly intervals.</th>
<th><strong>Initial:</strong> 1 mg/24 hours, increased as needed by 1 mg/24 hours at weekly intervals.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Do not use the same site more than once every 14 days.</strong></td>
<td><strong>Max recommended doses:</strong> 6 mg/24 hours (early disease) &amp; 8 mg/24 hours for (advanced disease)</td>
<td><strong>Max recommended dose:</strong> 3 mg/24 hours.</td>
</tr>
<tr>
<td><strong>The required dose may be achieved using single or multiple patches.</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### References

1. Neupro (rotigotine) [prescribing information]. Smyrna, GA: UCB Inc; January 2019

### Review History

- 02/25/08 - Reviewed
- 04/15/08 - Implemented
- 08/13/12 - Updated (Neupro reintroduced & new indication; 7/30/12 file)
- 11/25/13 - Reviewed
- 11/24/14 - Reviewed
- 11/27/17 - Reviewed
- 04/17/19 - Reviewed

### Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.